Summary by Futu AI
On December 31, 2023, a Schedule 13G was filed with the SEC by Ameriprise Financial, Inc. and several associated entities, collectively referred to as the Ameriprise Entities, regarding their holdings in Altimmune, Inc. The filing indicates that Ameriprise Financial, Inc., along with TAM UK International Holdings Limited, Threadneedle Holdings Limited, TAM UK Holdings Limited, Threadneedle Asset Management Holdings Limited, TC Financing Ltd, Threadneedle Asset Management Limited, and Threadneedle Investment Services Limited, have a shared voting and dispositive power over a significant number of shares in Altimmune. Specifically, Ameriprise Financial, Inc. reported shared voting and dispositive power over 4,183,682 shares, representing 7.79% of the class, while the other entities each reported shared power over 4,013,211 shares, representing 7.47% of the class. The entities are organized under the laws of Delaware, England, and Wales. The filing was certified by Michael G. Clarke, Senior Vice President of Ameriprise Financial, Inc., on February 14, 2024, stating that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of Altimmune, Inc.